Valuation: UCB

Market Cap 53.88B 60.47B 49.28B 44.88B 84.6B 5,714B 86.88B 592B 237B 3,026B 227B 222B 9,549B P/E 2026 *
25.5x
P/E 2027 * 21.8x
Enterprise Value 54.11B 60.73B 49.5B 45.08B 84.97B 5,739B 87.26B 595B 238B 3,039B 228B 223B 9,591B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 5.23x
Free-Float
61.59%
Yield 2026 *
0.52%
Yield 2027 * 0.53%
1 day+2.69%
1 week+3.64%
Current month+3.13%
1 month+44.45%
3 months+26.61%
6 months+25.63%
Current year+21.63%
1 week 275.5
Extreme 275.5
292.2
1 month 197.45
Extreme 197.45
292.2
Current year 197.45
Extreme 197.45
292.2
1 year 197.45
Extreme 197.45
292.2
3 years 65.4
Extreme 65.4
292.2
5 years 65.4
Extreme 65.4
292.2
10 years 54.84
Extreme 54.84
292.2
Manager TitleAgeSince
Chief Executive Officer 67 31/12/2014
Director of Finance/CFO 60 30/06/2020
Chief Tech/Sci/R&D Officer 59 30/04/2024
Director TitleAgeSince
Director/Board Member 55 31/12/2011
Director/Board Member 67 31/12/2014
Director/Board Member 56 23/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.69%+3.64%+33.92%+318.88% 60.47B
-2.00%+1.21%+50.17%+133.59% 1,263B
-0.49%-0.11%+47.80%+81.21% 665B
-0.58%+0.91%+35.36%+107.81% 521B
-1.06%-2.49%+47.76%+65.17% 387B
-0.58%+2.06%+76.98%+43.14% 371B
-0.10%+1.38%+32.03%+59.21% 310B
+0.13%+7.59%+12.79%+36.65% 293B
-2.38%+1.56%+46.29%+71.50% 259B
-2.40%+2.92%+39.05%+110.06% 216B
Average -0.56%+5.48%+42.21%+102.72% 434.59B
Weighted average by Cap. -1.01%+5.94%+45.28%+94.54%

Financials

2026 *2027 *
Net sales 8.91B 9.99B 8.15B 7.42B 13.98B 945B 14.36B 97.87B 39.13B 500B 37.52B 36.71B 1,578B 9.91B 11.12B 9.06B 8.25B 15.56B 1,051B 15.98B 109B 43.54B 557B 41.74B 40.84B 1,756B
Net income 2.18B 2.45B 2B 1.82B 3.43B 232B 3.52B 24.01B 9.6B 123B 9.2B 9B 387B 2.53B 2.84B 2.31B 2.1B 3.97B 268B 4.07B 27.76B 11.1B 142B 10.64B 10.41B 448B
Net Debt 233M 262M 213M 194M 366M 24.74B 376M 2.56B 1.03B 13.1B 983M 962M 41.35B -2.02B -2.26B -1.84B -1.68B -3.16B -214B -3.25B -22.14B -8.85B -113B -8.49B -8.31B -357B
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
05/11/26 €290.20 +2.69% 256,291
04/11/26 €282.60 +2.21% 245,301
03/11/26 €276.50 -0.58% 206,880
02/11/26 €278.10 -1.17% 220,594
30/10/26 €281.40 +0.50% 279,985
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
282.60EUR
Average target price
291.58EUR
Spread / Average Target
+3.18%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB